Meeting
2019 Gastrointestinal Cancers Symposium
A randomized clinical trial of chemotherapy with gemcitabine/cisplatin/nabpaclitaxel with or without the AXL inhibitor bemcentinib (BGB324) for patients with advanced pancreatic cancer.
Authors
Muhammad Shaalan Beg
The University of Texas Southwestern Medical Center, Dallas, TX
Muhammad Shaalan Beg , Andrew M. Lowy , Peter J. O'Dwyer , Gayle S. Jameson , Erkut Hasan Borazanci , Hitendra Patel , Clare Massey , Julia Schoelermann , James Lorens , Farjana Fattah , Kimberli Crane , Erin Fenske Williams , Jatan Clark , Daniel D. Von Hoff , Rolf A. Brekken
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT03649321
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr TPS473)
DOI
10.1200/JCO.2019.37.4_suppl.TPS473
Abstract #
TPS473
Poster Bd #
Q12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.
First Author: Tara Elisabeth Seery
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Biomarker-oriented study of pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer: A phase 2 trial-in-progress.
First Author: Jeesun Yoon
Poster
2021 ASCO Annual Meeting
Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.
First Author: Andrew Oar
Poster
2021 Gastrointestinal Cancers Symposium
AGIG chemo-immunotherapy in patients with advanced pancreatic cancer: A single-arm, single-center, phase II study.
First Author: Wangshu Dai